Drug Utilization Study of Antiplatelet in Thrombotic Stroke Patients: Studi Penggunaan Antiplatelet Pada Pasien Stroke Trombotik

samirah samirah; Rafifah Fadhilah; Rifdah Atikah Safitri; Abdulloh Machin; Suharjono; Nafa Rosyida Zanuba

doi:10.53342/pharmasci.v10i2.483

Authors

samirah samirah Departemen Farmasi Praktis, Universitas Airlangga
Rafifah Sarjana Farmasi, Fakultas Farmasi, Universitas Airlangga
Rifdah Atikah Safitri Magister Farmasi Klinis, Fakultas Farmasi, Universitas Airlangga
Abdulloh Machin Departemen Neurologi, Rumah Sakit Universitas Airlangga
Suharjono Universitas Airlangga
Nafa Rosyida Zanuba Universitas Airlangga

DOI:

https://doi.org/10.53342/pharmasci.v10i2.483

Keywords:

antiplatelet, stroke trombotik, studi penggunaan obat, Drug-related problems

Abstract

Stroke is the mayor cause of death and disability in Indonesia, with the thrombotic stroke being is the leading cause. Thrombotic stroke occurs due to the formation of a thrombus in the brain’s blood vessels, necessitating antiplatelet therapy to prevent recurrent stroke and other cardiovascular diseases. This study aim to identify pattern of antiplatelet therapy, adverse drug reaction, as well as drug-drug interaction related to antiplatelet. A total of 50 adult thrombotic stroke inpatient was observed in this observational-retrospective study. The most frequent antiplatelet used were acetosal (40%), clopidogrel (28%), followed by acetosal clopidogrel combination (28%), and acetosal-cilostazol combination (4%). In this study, 60% of ADR was identified, of which 16% was nausea and vomiting and 44% was dyspepsia. Five potential drug-drug interaction were identified, including acetosal-ACE inhibitor (6%), acetosal-NSAID (24%), Clopidogel-PPI (10%), and Clopidogrel-Statin (48%).

References

1. Lindsay M., Norving B, Sacco R., Brainin M, Hacke W, Martians S, et al. Global Stroke Fact Sheet 2019 World Stroke Organization [Internet]. 2019. Available from: https://www.worldstroke.org/assets/downloads/ WSO_Fact-sheet_15.01.2020.pdf

2. Venketasubramanian N, Yoon BW, Pandian J, Navarro JC. Stroke epidemiology in south, east, and south-east asia: A review. J Stroke. 2017;19(3):286–94..

3. Kementrian Kesehatan. Survei Kesehatan Indonesia (SKI) Dalam Angka. 2023.

4. PERDOSSI. Guideline Stroke. 2011.

5. AHA. 2022 Heart Disease and Stroke Statistics Update Fact Sheet At-a-Glance [Internet]. 2022 [cited 2023 Jul 8]. Available from: https://www.heart.org/-/media/PHD-Files- 2/Science-News/2/2022-Heart-and-Stroke-Stat- Update/2022-Stat-Update-At-a-Glance.pdf

6. Astuti AT, Subanti S, Susanti Y. Regresi Logistik Biner untuk Mengetahui Faktor Risiko yang

Mempengaruhi Stroke Non-Hemoragik pada Usia Produktif. In: Prosiding Konferensi Nasional Penelitian Matematika dan Pembelajarannya. Surakarta: Universitas Muhammadiyah Surakarta; 2019.

7. Assaufi MH, Ardana M, Masruhim MA. Evaluasi Terapi Obat Antiplatelet Pada Pengobatan Pasien Stroke Di Instalasi Rawat Inap Rsud Am Parikesit Tenggarong Periode Tahun 2014. In: Prosiding Seminar Nasional Kefarmasian Ke-4. 2016. p. 20-21 Samarinda 20-21 Oktober 2016.

8. Kementrian Kesehatan RI. Pedoman Nasional Pelayanan Kedokteran Tata Laksana Stroke. 2019. 1–151 p.

9. Kleindorfer DO, Towfighi A, Chaturvedi S, Cockroft KM, Gutierrez J, Lombardi-Hill D, et al. 2021 Guideline for the prevention of stroke in patients with stroke and transient ischemic attack; A guideline from the American Heart Association/American Stroke Association. Stroke. 2021. 364–467 p.

10. Younis LS, Mohammed IM, Najah HT, Haider AM. Antiplatelet Drugs Overview. GSC Biol Pharm Sci. 2020;10(01):81–9.

11. Megawati S, Rahmawati R, Fathonah N. Evaluasi Penggunaan Obat Antiplatelet Pada Pasien Stroke Iskemik Di Instalasi Rawat Inap Rumah Sakit Umum Kabupaten Tangerang Tahun 2019. J Farmagazine. 2021;8(1).

12. Strom B., Kimmel S. Textbook of Pharmacoepidemiology. 3rd ed. New York: Wiley Blackwell; 2021.

13. Kurniasari D. Evaluasi Rasionalitas Obat Antiplatelet Pada Pasien Stroke Rawat Inap RSUD Dr. Moewardi Surakarta Periode 2016. 2017.

14. Wang Y, Dai Y, Zheng J, Xie Y, Guo R, Guo X, et al. Sex difference in the incidence of stroke and its corresponding influence factors: Results from a follow-up 8.4 years of rural China hypertensive prospective cohort study. Lipids Health Dis. 2019;18(1):1–10.

15. Kesuma NMTS, Dharmawan DK, Fatmawati H. Gambaran faktor risiko dan tingkat risiko stroke iskemik berdasarkan stroke risk scorecard di RSUD Klungkung. Intisari Sains Medis. 2019;10(3):720–9.

16. Boehme AK, Esenwa C, Elkind MSV. Stroke Risk Factors, Genetics, and Prevention. Circ Res. 2017;120(3):472–95.

17. Yousufuddin M, Young N. Aging and Ischemic Stroke. Aging (Albany NY). 2019;11(9):2542– 4.

18. Cipolla MJ, Liebeskind DS, Chan SL. The importance of comorbidities in ischemic stroke: Impact of hypertension on the cerebral circulation. J Cereb Blood Flow Metab. 2018;38(12):2129–49.

19. Feigin VL, Norrving B, Mensah GA. Global Burden

of Stroke. Circ Res. 2017;120(3):439–48.

20. Goldstein LB, Adams R, Alberts MJ, Appel LJ, Brass LM, Bushnell CD, et al. Primary prevention of ischemic stroke. A guideline from the American Heart Association/American Stroke Association Stroke Council: Cosponsored by the Atherosclerotic Peripheral Vascular Disease Interdisciplinary Working Group; Cardiovascular Nursing Counc. Vol. 37, Stroke. 2006. 1583–1633 p.

21. Kamarova M, Baig S, Patel H, Monks K, Wasay M, Ali A, et al. Antiplatelet Use in Ischemic Stroke. Ann Pharmacother. 2022;56(10):1159–73.

22. Hackam DG, Spence JD. Antiplatelet therapy in ischemic stroke and transient ischemic attack: An overview of major trials and meta-analyses. Stroke. 2019;50(3):773–8.

23. Paciaroni M, Ince B, Hu B, Jeng JS, Kutluk K, Liu L, et al. Benefits and Risks of Clopidogrel vs. Aspirin Monotherapy after Recent Ischemic Stroke: A Systematic Review and Meta- Analysis. Cardiovasc Ther. 2019;2019:1–12.

24. Yang Y, Huang Z, Zhang X. Efficacy and safety of clopidogrel and/or aspirin for ischemic stroke/transient ischemic attack. Medicine (Baltimore). 2021;100(50):e27804.

25. Toyoda K, Uchiyama S, Hoshino H, Kimura K, Origasa H, Naritomi H, et al. Protocol for Cilostazol Stroke Prevention Study for Antiplatelet Combination (CSPS.com): A randomized, open-label, parallel-group trial. Int J Stroke. 2015;10(2):253–8.

26. Schror K, Voelker M. NSAIDS and Aspirin: Recent Advances and Implications for Clinical Management. In: Lanas A, editor. NSAIDs and Aspirin. Springer Charm; 2016.

27. Preston CL. Stockley’s Drug Interaction Pocket Companion 2015. London: Pharmaceutical Press; 2014.

28. Polzin A, Zeus T, Schror K, Kelm M, Hohlfield T. Dipyrone (metamizole) can nullify the antiplatelet effect of aspirin in patients with coronary artery disease. J Am Coll Cardiol. 2013;62(18):1725–6.

29. Karalliedde L., Clarke S., Gotel U, Karalliedde J. Adverse Drug Interaction A Handbook for Prescribers. 2nd ed. CRC Press; 2016.